MYC and neoplasm: These data provide therapeutic proof of principle that inhibition of MYC signaling through αvβ3-targeted drug delivery of the small molecule MI3-PD could be used to reduce M2 macrophages in the tumor microenvironment while sparing M1 antitumor macrophages.